Small Lymphocytic Lymphoma
📧 Sign up to get email alerts when something new happens for Small Lymphocytic Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies [NA]
This clinical trial update describes an evaluation of MTM-H-001 injection in adults with relapsed or refractory B-cell lymphomas, with the s…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) [Phase 3]
Phase 3 study MK-1026-008/BELLWAVE-008 is evaluating nemtabrutinib against chemoimmunotherapy in previously untreated chronic lymphocytic le…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial [Phase 2]
Phase 2 LonGEVity trial evaluating a sequence of venetoclax and obinutuzumab followed by epcoritamab for untreated chronic lymphocytic leuke…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). [Phase 3]
This Phase 3 clinical trial compares Nemtabrutinib plus Venetoclax versus Venetoclax plus Rituximab in second-line or relapsed/refractory ch…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib [EARLY_Phase 1]
An early-phase trial evaluating immune profiling of first-line pirtobrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies [Phase 1]
Phase 1 clinical trial update of BGB-21447, a Bcl-2 inhibitor developed by BeOne Medicines, evaluating safety and preliminary activity in mu…
-
CLINICAL_TRIALS trial_result · 2026-03-11Clinical Trial Update: Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas [Phase 1, Phase 2]
Phase 1/2 study evaluating the combination of lenalidomide with DA-EPOCH-R in MYC-associated B-cell lymphomas has completed, and results hav…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:
A clinical trial update describes an economic analysis comparing early versus delayed therapy in newly diagnosed asymptomatic high-risk chro…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia [Phase 2]
This Phase 2 clinical trial update reports on a combination therapy of ibrutinib, fludarabine phosphate, cyclophosphamide, and obinutuzumab …
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating ixazomib citrate with rituximab in indolent B-cell non-Hodgkin lymphoma has posted results.
-
CLINICAL_TRIALS trial_result · 2026-03-04Clinical Trial Update: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) [Phase 1, Phase 2]
Clinical Trial Update on the ALPHA2 Phase 1/2 study evaluating ALLO-501A anti-CD19 allogeneic CAR T cells in adults with relapsed/refractory…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
BeiGene's BGB-11417 is being studied in a Phase 2 trial for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphom…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) [Phase 1, Phase 2]
This clinical trial evaluates the safety and efficacy of JCAR017 in relapsed or refractory chronic lymphocytic leukemia and small lymphocyti…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias [Phase 1, Phase 2]
Clinical trial update on an anti-CD19 CAR-T cell therapy being evaluated in Phase 1/Phase 2 for various leukemias and lymphoid cancers; recr…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab [Phase 1, Phase 2]
BeiGene announced completion and posted results for a Phase 1/2 study of BGB-10188 as monotherapy and in combination with zanubrutinib and t…
-
FDA approval · 2026-02-19FDA Approved: CALQUENCE — Supplemental Application (AstraZeneca Pharmaceuticals LP)
FDA approves a supplemental application for CALQUENCE (acalabrutinib) submitted by AstraZeneca Pharmaceuticals LP.
-
CLINICAL_TRIALS trial_result · 2026-02-19Clinical Trial Update: Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
Post-marketing surveillance study in Japan evaluating Calquence (acalabrutinib) as first-line therapy for previously untreated chronic lymph…
-
CLINICAL_TRIALS trial_result · 2026-02-19Clinical Trial Update: Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia [Phase 2]
Phase 2 clinical trial update evaluating venetoclax in combination with ibrutinib for chronic lymphocytic leukemia and small lymphocytic lym…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi [Phase 2]
This clinical trial update describes a Phase 2 study evaluating pirtobrutinib in combination with venetoclax for patients with chronic lymph…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia [Phase 2]
This is a Phase 2 clinical trial update on acalabrutinib combined with venetoclax or obinutuzumab for treatment-naive chronic lymphocytic le…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 3]
A Phase 3 clinical trial comparing acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphoc…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome [Phase 2]
Phase 2 clinical trial evaluating a triple-drug regimen (atezolizumab, obinutuzumab, and venetoclax) for chronic lymphocytic leukemia, small…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. [Phase 1]
A Phase 1 clinical trial evaluating oral LP-168 in relapsed or refractory B-cell malignancies is recruiting. Target conditions include CLL/S…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies [Phase 1]
Phase 1 clinical trial from Mayo Clinic is evaluating BAFFR-based CAR-T cells with lymphodepletion (fludarabine and cyclophosphamide) for re…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 clinical trial update examining the combination of pirtobrutinib and venetoclax with measurable residual disease (MRD) detection for…